Breathing hydroxy gas to relieve Long COVID symptoms
Randomised, Placebo-controlled, Double-blind Cross-over Study to Investigate the Therapeutic Effects of an Inhaled Hydrogen/Oxygen Mixture to Improve Long COVID Symptoms
This study is testing if breathing in a special gas made of hydrogen and oxygen can help people with Long COVID feel less pain, breathlessness, and fatigue.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 25 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Oxford Brookes University Academic / other |
| Locations | 1 site (Oxford, Oxfordshire) |
| Trial ID | NCT06159296 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effects of inhaling hydroxy gas, a mixture of hydrogen and oxygen, on symptoms associated with Long COVID. Participants will self-administer the treatment at home using a machine that delivers the gas through a nasal cannula for at least 2 hours a day over a 3-week period. The study employs a randomized, placebo-controlled design, where participants will alternate between receiving hydroxy gas and normal air, with a washout period in between. The primary aim is to determine if this treatment can alleviate pain, breathlessness, and fatigue in patients suffering from post-acute COVID-19 syndrome.
Who should consider this trial
Good fit: Ideal candidates are individuals experiencing moderate to severe pain, breathlessness, or fatigue due to Long COVID who live within an hour's drive of the Oxford Brookes campus.
Not a fit: Patients with pre-existing secondary diseases, chronic respiratory conditions, or those who have required ICU treatment for COVID may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a new, accessible option for patients struggling with Long COVID symptoms.
How similar studies have performed: While the approach of using inhaled gas for treatment is innovative, similar studies on Long COVID treatments have shown mixed results, making this a novel exploration.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Any moderate or severe pain, breathlessness, or fatigue associated with long COVID * live within an hour's drive of the Oxford Brookes campus Exclusion Criteria: * Pre-existing secondary diseases; tumors, mental health conditions, chronic respiratory conditions such as Chronic Obstructive Pulmonary Disease (COPD), and cardiac disease * Previous requirement of ICU treatment due to COVID * Acute or chronic infections or no pre-existing autoimmune diseases
Where this trial is running
Oxford, Oxfordshire
- Oxford Brookes University — Oxford, Oxfordshire, United Kingdom (Recruiting)
Study contacts
- Principal investigator: Shakeeb H Moosavi, PhD — Oxford Brookes University
- Study coordinator: Shakeeb Moosavi, PhD
- Email: smoosavi@brookes.ac.uk
- Phone: +44 (0)1865 483257
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.